Endogenous dipeptide that modulates IGF-1 bioavailability in the brain.
Typical dose range: 10–50 mg
Frequency: Daily
Route: Oral
Half-life: Short
Evidence level: Pre-clinical + early clinical
Researched at the University of Auckland for stroke recovery. Available as a research-grade supplement rather than an injectable peptide.